Real World Evidence (rwe) - Pharma

Relevant Publications

Key results from observational studies and real-world evidence of sodium-glucose cotransporter-2 inhibitor effectiveness and safety in reducing cardio-renal risk.

Issue Release: 2024

Application of Multi-Criteria Decision Analysis (MCDA) to Prioritize Real-World Evidence Studies for Health Technology Management: Outcomes and Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration.

Issue Release: 2024

Data Science Methods for Real-World Evidence Generation in Real-World Data.

Issue Release: 2024

Real-World Evidence to Reinforce Clinical Trial Evidence in Health Technology Assessment: A Critical Review of Real-World Evidence Requirements from Seven Countries and Recommendations to Improve Acceptance.

Issue Release: 2024

The FAIRification of research in real-world evidence: A practical introduction to reproducible analytic workflows using Git and R.

Issue Release: 2024

[The application of real-world evidence in drug regulatory decision-making].

Issue Release: 2024

Observational studies to emulate randomized trials: Some real-world barriers.

Issue Release: 2024

The Amager Project IV: suicidal behavior and aftercare: real world data (RWD) from a prospective observational project.

Issue Release: 2024

Comprehensive comparative efficacy and safety of potent P2Y inhibitors in patients undergoing coronary intervention: A systematic review and -analysis.

Issue Release: 2024

Increase transparency and reproducibility of real-world evidence in rare diseases through disease-specific Federated Data Networks.

Issue Release: 2024

Harnessing the Potential of Real-World Evidence in the Treatment of Colorectal Cancer: Where Do We Stand?

Issue Release: 2024

Establishment of RWS guidance reflecting contributions of China to regulatory science.

Issue Release: 2024

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15.

Issue Release: 2024

Real-World Evidence to Inform Regulatory Decision Making: A Scoping Review.

Issue Release: 2024

Patient listening on social media for patient-focused drug development: a synthesis of considerations from patients, industry and regulators.

Issue Release: 2024

Navigating the Landscape of Liver Cancer Management: Study Designs in Clinical Trials and Clinical Practices.

Issue Release: 2024

The Use of Real-World Evidence for Regulatory Decisions in China.

Issue Release: 2024

Utility of real-world evidence in biosimilar development.

Issue Release: 2024

Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease.

Issue Release: 2024

A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks.

Issue Release: 2024

How Are Participants Protected?

How Does Cellular Stress Impact Drug Development?

What is Geriatric Care in Pharma?

What is Cellular Stress?

What is an Abbreviated New Drug Application (ANDA)?

What is the Future of the Pharmacy Profession?

What are the Phases of Clinical Trials?

How Can Technology Aid in Management?

What is Medication Management?

Why do Pharma Companies Use CROs?

Partnered Content Networks

Relevant Topics